J Korean Ophthalmol Soc.  2003 May;44(5):1198-1204.

Usefulness of Newly Developed Film Form Drug Delivery System that Inhibits Lens Epithelial Cell Proliferation

Affiliations
  • 1Laboratory of Ophthalmology and Visual Science, College of Medicine, The Catholic university of Korea, Seoul, Korea. ckjoo@catholic.ac.kr

Abstract

PURPOSE
To develop a therapeutic drug delivery system which inhibits lens epithelial cells proliferation. METHODS: Chitosan, a natural polymer, which is biocompatible and biodegradable was mixed with glycerol with a certain ratio to make it an asceptic film form. Water content and degradability of this film was determined. During the construction of film, 5-fluorouracil (5FU) was added to make of film containing 5FU. Drug release was checked with high performance liquid chromatography (HPLC). Cell cytotoxicity of this film was determined with MTT (3-(4, 5-dimethylathiazol-2yl)-2, 5-diphenyl tetrasoliumbromide) assay. RESULTS: Newly constructed film did not show any cell cytotoxicity against human lens epithelial cells, HLE-B3. In the lysozyme-free PBS, 62% of C/Gly-1 and 53% of C/Gly-0.7 were degraded respectively after 4 weeks. CONCLUSIONS: This film was designed to be inserted between artificial crystalline and posterior capsule. With its transparency, this film may not interfere the vision of patient. This film is also completely degradable in the lysozyme containing condition. With these characteristics, this film may be used in the drug delivery system that inhibits the formation of after cataract.

Keyword

After cataract; Cataract; Drug delivery system

MeSH Terms

Cataract
Chitosan
Chromatography, Liquid
Crystallins
Drug Delivery Systems*
Epithelial Cells*
Fluorouracil
Glycerol
Humans
Muramidase
Polymers
Water
Chitosan
Crystallins
Fluorouracil
Glycerol
Muramidase
Polymers
Water
Full Text Links
  • JKOS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr